ELTP Discussion 11/20/2014 18:58:07 $ELTP
No problem; NH
ELTP Discussion 11/20/2014 18:58:07 $ELTP
No problem; NH will just go to the well for LPC Good Deal III and the huge dilution that will bring. No wonder ELTP can't make any headway.
Quote:
Nobody can Stop US!!
From selling shares; correct; but what can start us to doing something else?
Good news after the CC ** BOOM ** PPS explosion upwards!!!!!!
Quote:
unless the dives are considered spectacular
Yesterday the PPS did do a spectacular dive.
Speculation is good for the PPS but reality is bad.
Correct; NasRAT needs to stop doing CCs and PRs and let speculation that things are great drive the PPS up.
Mazeppa: Lasers addressed this this am; it didn't sound like a game changer: see #135593.
Elite is still early for the party. My only question is if Purdue or Elite has the better technology.
C H E E R $ !
Quote:
ELTP is currently WAY over-sold, and WAY undervalued.
How is that figured; the only thing they have to sell now is shares and they will soon max out the AS.
I don't know about the chart but I do know that ELTP has been lingering in and around the high .25 and very low .30s far longer than 2 to 3 weeks. The one exception was the .335 achieve in the hype up to the CC and look what happened to that one. Should we have celebrated .335 and the excitement of the FDA meetings?
So is Isradipine. At that pace we may see an opioid drug in a few years if at all. Just make sure the have the drugs to produce if and when approved otherwise tact another year to the target date. No funny but true.
Purdue got an ART approved today:http://news.yahoo.com/fda-approves-hard-abuse-hydrocodone-pill-181653518--finance.html
This is not exactly what I was hoping to see. I do agree with all that the FDA delay was a non-issue, and we traded down due to s/t traders hoping for a quick pop if the news that came out was good...but realistically, the FDA was not about to tell them to file or make final decision regarding studies within one day of meeting. But, now this--is it a game-changer against us, or just one more competitor? Maybe we make out well being the first to the morphine market...but looks like we lost the race to hydrocodone.
Would like to hear any thoughts on this.
GLTA,
Maz
wow that is completely false. for example, the company is basically profitable- wrong, even excluding R&D ( a very strange concept, the company still lost 500k.
LOL LOL thanks for buying and believing in ELITE.
Despite all my complaints. I still think Elite will be successful, just added another 50 Gs at 28 cent.
I do believe many small investors dumped and were in it for a quick buck. I think it will stabilize here and move slowly north. Any drug stock will give an investor a wild ride - especially one that is in the early stages of new drug development. Max
Yes because folks are accumulating and will run the stock until the time is right just like before..,,except next time instead of .10 to .97, it will be from .30 to $3.00
And again there has been absolutely nothing presented to think oitherwise.
Wow. Almost everything just posted is false again. This is a generic drug. All trials have passed beautifully. That is how drugs get approved so saying there is no reason is opposite how it works. There is every reason and everyone here knows it.
The company is basically profitable and growing outside of R&D so you posted more false information there...
Share count is pretty low really and they have plenty of cash.
And did we forget Nasrat buying almost another 1m shares on the open market?
OK - It looks like 2 to 3 weeks of an overbought period being kicked like a dead horse to make it sound like it's the "norm" - when we can all see from the CHART that it's not. Thanks for asking!
Here's those POSITIVE STUDIES again to confirm / support that Elite's ART product(s) WILL be approved.
ELITE PHARMACEUTICALS RELEASES POSITIVE TOP LINE HUMAN ABUSE LIABILITY DATA FOR ELI-200, AN OPIOID ABUSE DETERRENT PRODUCT
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...
Continue Reading
Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...
Continue Reading
Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...
Continue Reading
Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...
Continue Reading
American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....
Continue Reading
Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...
Continue Reading
Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...
Continue Reading
Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...
Continue Reading
Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...
Continue Reading
Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...
Continue Reading
Top 5 Most Recently Viewed Articles
KeyCorp Welcomes Mohit Ramani as Chief Risk Officer KeyCorp (NYSE: KEY), a prominent figure in the bank-based financial services industry, has made an important decision by announcing the appointment of Mohit (Mo) Ramani as its new Chief Risk Officer. This notable addition to the executive leadership team is seen as a strategic step towards enhancing the company's risk...
Continue Reading
Exploring the Growth of the Quaternary Ammonium Salts Market The global quaternary ammonium salts market is on a remarkable growth trajectory, anticipated to reach a valuation of US$ 1,088.0 Million by the year 2034. With a robust CAGR of 5.9% from 2024 to 2034, this market is driven by increasing consumer awareness regarding hygiene and safety. Factors Driving Market...
Continue Reading
Generac Prepares for Earnings Release and Conference Call Generac Holdings Inc. (NYSE: GNRC), known as a prominent leader in energy technology solutions, is gearing up for an important announcement. The company plans to unveil its fourth quarter and full-year 2024 financial results just before the market opens. The anticipated date for this release is set for an upcoming...
Continue Reading
Significant Presentation at EURetina 2025 AAVantgarde Bio, a leading clinical-stage biotechnology company, is poised to present updated outcomes from its LUCE-1 clinical trial at the prestigious 25th European Society of Retina Specialists (EURETINA) Annual Congress in Paris. This event, scheduled from September 4-7, 2025, offers a vital platform for advancing discussions...
Continue Reading
Understanding the Value of WisdomTree Funds WisdomTree is known for its innovative approach to exchange-traded funds (ETFs). As investors seek ways to maximize their asset portfolios, understanding the net asset values (NAVs) of these funds becomes essential. In this article, we delve into various funds offered by WisdomTree, highlighting their date of valuation and key...
Continue Reading